Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy and Radiotherapy for NSCLC Brain Metastases
NCT05584267Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hunan Cancer Hospital. Primary endpoints: Intracranial Progression-Free Survival at 2 years and Systemic Progression-Free Survival at 2 years. Started Dec 2022; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05584267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584267.